A study was conducted to investigate a novel approach to the prophylaxis of schizophrenic relapse. The treatment strategy comprised brief intermittent courses of neuroleptic agents begun as soon as non-psychotic symptoms believed to be early signs of relapse appeared. Fifty four stable, remitted outpatients meeting the American Psychiatric Association's DSM-III criteria for schizophrenia were randomised double blind to receive brief intermittent treatment with either active or placebo depot neuroleptic injections. Only three patients given placebo injections and two controls were admitted to hospital during one year of follow up. Eight (30%) of the patients given placebo injections and only 2 (7%) ofthe controls, however, had a recurrence of schizophrenic symptoms. Patients given placebo injections experienced fewer extrapyramidal side effects and showed a trend towards a reduction in tardive dyskinesia. Dysphoric and neurotic symptoms were identified before eight out of 11 relapses, and these symptoms were more frequent in patients given placebo depot injections.
Introduction
The use of continuous neuroleptic treatment to prevent exacerbations of schizophrenic illness is virtually universal. Its efficacy is supported by a considerable weight of evidence from placebo controlled studies showing the superiority of neuroleptic treatment in preventing relapse.' Enthusiasm for continuous prophylaxis with neuroleptics, however, has been tempered in recent years by an increasing recognition of the risks, both actual and potential, of continuous drug exposure. The most alarming is the risk of tardive dyskinesia, which is estimated to occur in up to 41% of outpatients2 and may be irreversible. The occurrence of distressing extrapyramidal side effects is also well recognised. The greasy masked facies, stooped posture, "dancing feet," and slow, shuffling gait mark some patients out in a crowd and have been linked to the occurrence of depressive and dysphoric symptoms,3 4 impaired social functioning, and exacerbation of the negative symptoms of the illness. 6 Recognition of these risks has prompted a search for alternative strategies of treatment designed to prevent or attenuate relapse while reducing drug exposure and side effects. One such strategy, first suggested by Herz and Melville, aims at identifying the earliest signs of decompensation with prompt but time limited treatment during such periods. 7 The strategy entails keeping patients drug free and regularly monitoring their clinical state and as such offers the opportunity for considerable reductions in drug exposure. An uncontrolled pilot investigation,8 preliminary reports,9-"1 and a controlled study'2 have confirmed the feasibility of this approach.
The possibility of recognising signs suggestive of impending relapse is evidenced in Herz and Melville's retrospective study of the early signs of schizophrenic decompensation.7 It is well recognised that depressive symptoms are a frequent accompaniment of schizophrenic illness'3 14 and it has been suggested that they form part of the process of decompensation, being more frequent at the onset of acute psychosis and subsiding in parallel with psychotic manifestations.'3 16 Herz and Melville, following up previous, mostly anecdotal or unsystematic reports reviewed by Docherty and colleagues,'7 found that such affective changes together with the emergence of other neurotic symptoms bore a potentially valuable temporal relation to the onset of relapse.7
In a retrospective study of 145 chronic schizophrenics and 80 family members Herz and Melville found that 102 of the patients and 74 of the family members noted mood changes and neurotic symptoms before the onset of relapse.7 These symptoms were mostly of a non-specific type and not clearly related to the phenomena of psychosis. In more than half of the cases the duration of such symptoms, which they termed prodromal symptoms, was more than one week, after which relapse occurred. Herz and Melville argued that these prodromal symptoms represented the early stages of schizophrenic decompensation and hypothesised that the prompt introduction of neuroleptics at these stages would ameliorate prodromal symptoms and prevent subsequent progression to relapse. In a retrospective case note study of patients receiving early pharmacotherapeutic intervention for schizophrenic relapse, Heinrichs and colleagues reported that 24 of 38 patients evidenced insight into their illness in the early stages of decompensation. Of these, only two were admitted to hospital during relapse, the remainder being successfully restabilised as outpatients. 18 
HYPOTHESES
A strategy of prophylaxis based on intermittent neuroleptic treatment for early signs of relapse offers several potential benefits in comparison with the conventional strategy of continuous neuroleptic treatment. We expected that these would principally be derived from reduced exposure to neuroleptic agents and include a reduction in persistent side effects such as dyskinesia, akathisia, akinesia, and sedation. We further hypothesised that reduction in persistent side effects would lead to improvements in social functioning, and though we recognised that such a strategy would lead to an increase in the frequency of relapse, we reasoned that by prompt recognition and treatment of early signs such relapses could be attenuated to the point that their negative effects would be outweighed by the potential benefits of the new strategy. We expected our findings to accord with those found in so called "low dose" studies, in which reducing the dose of maintenance treatment to up to one tenth leads to an increase in the frequency of symptomatic exacerbations but no change in the frequency of serious relapse as evidenced by admission to hospital.9 120 This paper is a report of clinical outcome after one year in terms of symptoms, treatment, and side effects. Data on social outcome will be reported separately after a longer period of follow up. A record of the number of interventions additional to those scheduled together with the dose, frequency, and reasons for giving additional treatment was kept for each patient. Dose of depot fluphenazine was converted to haloperidol equivalents on the basis of notional clinical equipotency of 1 mg fluphenazine decanoate intramuscularly and 2 62 mg haloperidol by mouth. This dose equivalence is supported by data on the relative clinical potency of these drugs derived from comparison of outcome in controlled trials and dose-response studies23 but may overestimate the potency of the depot preparation as judged by relative plasma concentrations of active drug produced by a given dose. 24 Treatment ofprodromal symptoms continued for up to two weeks unless relapse occurred. Treatment of relapse was continued until four weeks after the remission of symptoms.
Methods
Patients were withdrawn from the double blind treatment and early intervention for prodromal symptoms if they (a) refused to comply with the treatment programme, (b) relapsed for a period of greater than eight weeks, or (c) relapsed on two or more occasions within six months. Patients withdrawn from double blind treatment were followed up under open treatment conditions until one year after the start ofthe trial and included in the analysis of outcome.
MEASURES
The Manchester scale is an eight item scale for rating psychotic symptoms on five points (0-4).26 It consists of both positive and negative symptoms of schizophrenia. It was administered by the psychiatrist at baseline and thereafter every two months. It was also administered every two weeks during relapse.
The global assessment scale consists of 10 grades of psychopathology and overall functioning on a scale of 0_100.26 It was administered together with the Manchester scale.
The Herz early signs questionnaire is the only scale specifically designed for rating the process of decompensation in schizophrenia.8 The questionnaire is meant to assess patients' perceptions of themselves and consists of 32 questions rated on five points of severity (O=absent, 5 =extreme). It was administered at baseline and every two months thereafter. It was also administered at the onset of prodromal symptoms and weekly for the subsequent two weeks.
The symptom check list 90 is a self rating inventory consisting of 90 items relating to affective and neurotic symptoms and psychoses. 27 The amount of distress engendered by each symptom is rated on a four point scale (0-4). The scale was rated before entry into the trial and every four weeks thereafter, either during clinic attendance or at home during visits by the community psychiatric nurse. The scale was also filled out at the onset ofprodromal symptoms and weekly for the subsequent two weeks.
The extrapyramidal rating scale is a modified Simpson-Angus rating scale. 28 The prevalence of global "non-liveliness," global parkinsonism, and specific extrapyramidal side effects was calculated by BMJ VOLUME 298 15 APRIL 1989 collapsing down item scores into simple present-absent ratings. The scale was rated at baseline and at six month intervals. Table I shows the baseline sociodemographic and clinical characteristics of the intermittent treatment and control groups. There was no significant difference between the groups in any baseline variable. The age at onset was slightly higher than might have been expected in an unselected sample and may reflect selection of a better prognostic group. Six patients were withdrawn from double blind treatment in the intermittent treatment group and five in the control group. Table III shows the outcome in all patients who were entered into the study. Relapse was significantly more frequent in the intermittent treatment group (eight patients) than in the controls (two), but this difference was not accompanied by any significant increase in the frequency of admission to hospital in the intermittent treatment group. In both groups the rate of admission was low (five patients), and high minimal global assessment scale scores during relapses and infrequent use of compulsory powers indicate that severe relapse was uncommon. Prodromal symptoms were identified prospectively (that is, before relapse) in eight of the 11 relapses.
Despite the increased rate of recurrence of psychotic symptoms in the intermittent treatment group there was no overall difference between this group (n=27) and the controls (n=27) in the regular bimonthly ratings of psychotic symptoms. Mean score on the Manchester scale did not differ significantly between the groups at baseline (table I), and mean group scores obtained bimonthly throughout the trial and compared at each time point failed to yield significant differences between the intermittent treatment group (median 1I4, range 0-9-2 0) and the controls (median 1-9, range 1-7-2-2) at any stage in the study (Mann-Whitney U tests). Parallel findings were obtained for global assessments of psychopathology and social functioning. Mean global assessment scale scores (table I) did not differ significantly between groups at baseline and ranged from 71 to 77 in controls (median 74) and from 75 to 80 in the intermittent treatment group (median 78) with no significant difference between groups at any bimonthly assessment (Mann-Whitney U tests).
When all treatment was taken into account, including that given to patients withdrawn early from double blind treatment and followed up openly, the intermittent treatment group, as predicted, received significantly less total treatment (haloperidol equivalents) than controls (table III) . 2 9 No of prodromal symptoms identified before relapse 2 6 Median (range) duration of relapse (days) 51 (11-90) (n=2) 32 BMJ VOLUME 298
PRODROMAL EPISODES
non-specific management in the form of supportive interventions by the psychiatrist or community psychiatric nurse. A total of 44 prodromal episodes, as operationally defined, were recorded in the whole study sample. Of these, eight occurred before relapses, the remaining 36 being isolated phenomena bearing no clear relation to relapse. As in the whole study sample, the intermittent treatment group received less total neuroleptic treatment despite more frequent use oforal haloperidol (table IV) . Table V shows the symptom check list 90 subscale scores before, during, and after the 44 prodromal episodes. Significant increases in subscale scores for depression, anxiety, phobic anxiety, obsessionality, and interpersonal sensitivity together with significant increases in scores for psychosis, paranoid symptoms, and global severity of distress occurred at the onset of prodromal symptoms compared with routine assessments within one month of the onset of prodromal symptoms. Scores on these scales reverted to values not significantly higher than those at baseline after two weeks of neuroleptic treatment (Wilcoxon matched pairs signed rank tests).
Individual item scores on the Herz early signs questionnaire obtained at the onset of prodromal symptoms were compared with those obtained at routine assessment conducted within two months of onset of each prodromal episode in order to characterise symptoms emergent at the onset of the episodes. As before, a pattern of emergence of a broad range of non-specific symptoms that could be regarded as dysphoric was observed. Table VI outlines the frequencies of these emergent symptoms.
MOVEMENT DISORDER Table VII shows the point prevalence of extrapyramidal side effects for both the intermittent treatment and control groups. At baseline controls had a greater prevalence of extrapyramidal side effects. These differences, however, did not achieve statistical significance. At both six and 12 months of follow up akathisia and non-liveliness were significantly less prevalent in the intermittent treatment group. At 12 months of follow up these patients also had a signifi- (45) 19 (43) 18 (41) 18 (41) 18 (41) 18 (41) 18 (41) 15 (34) 15 (34) 14 (32) 14 (32) 12 (27) 12 (27) 10 (23) 8 (18) 7 (16) 6 (14) 5 (11) 3 (7) 2 (5) 2 (5) cantly lower prevalence of gait abnormality and global parkinsonism.
In order to obtain an overall rating ofextrapyramidal side effects scores on individual items of the extrapyramidal rating scale were summed to produce a total extrapyramidal symptom score for each patient (table  VIII) . At baseline there was no difference between groups on this measure. At both six months and one year, however, total symptom scores were significantly lower in the intermittent treatment group. Table IX shows the point prevalence data for tardive dyskinesia. At baseline there was no difference between the groups. Point prevalence rose in the controls Mann-Whitney U test=98-0; 2 tailed p=0-0007 *Based on dose equivalence of 1 mg fluphenazine decanoate intramuscularly and 2-62 mg haloperidol by mouth. and remained comparatively stable in the intermittent treatment group in the one year follow up period. At one year the difference between the groups approached statistical significance (p=008), indicating a trend towards a lower prevalence in patients given intermittent treatment than in controls. The overall social effects of the brief intermittent treatment approach and the outcome after longer follow up are still under study and will be reported later.
COST EFFECTIVENESS COMPARISONS
The brief intermittent treatment strategy is more demanding of medical and nursing manpower than conventional continuous neuroleptic treatment. The amount of non-specific treatment in the form of supportive interventions by the psychiatrist and community psychiatric nurse was significantly greater within the brief intermittent treatment group than in patients receiving continuous neuroleptic treatment. This is not surprising, as such non-specific treatment was for the most part contingent on noting the development of prodromal symptoms or relapse. The educational component of the study, however, was limited to a single group session and we did not employ the intensive weekly group follow up utilised to monitor progress in other studies of early detection and treatment."2 The research psychiatrist and community psychiatric nurse were responsible for the clinical management of over 90 schizophrenic patients in the community during the study, including the 54 patients reported on in this paper who required detailed research evaluation. Our impression is that the additional non-specific treatment required in the brief intermittent treatment approach is not of such magnitude as to preclude use of the strategy in the normal clinical setting.
RELEVANCE OF PRODROMAL EPISODES
The theoretical rationale for a programme of treatment based on the early detection and treatment of prodromal symptoms is supported by the finding that eight out of 11 relapses were preceded by such symptoms. This finding is consistent with a previous retrospective study7 and attests to the feasibility of detecting and treating early signs of schizophrenic relapse.
The pattern of dysphoric and neurotic symptoms reported in prodromal episodes was not specific for schizophrenia. The exception to this finding was the frequent report of the fear of "going crazy" in our study, possibly because patients were trained to recognise the emergence of neurotic and dysphoric symptoms as indicating a relapse of their illness.
We emphasise that altogether some 44 prodromal episodes were recorded, of which 36 were isolated phenomena bearing no clear relation to relapse. The greater frequency of such episodes when patients were between treatments suggests that they may form part of the process of schizophrenic decompensation, in abeyance under the influence of neuroleptics. All our patients, however, were given oral haloperidol when these symptoms occurred. Because dysphoria is a common response to adverse life events and chronic difficulties which occur independently of illness, only a controlled study in which a random sample of prodromal episodes is blindly treated with neuroleptic or placebo would tell us if relapse would have followed these isolated prodromal episodes without treatment.
